MediWound (NASDAQ:MDWD) Receives "Buy" Rating from HC Wainwright

MediWound (NASDAQ:MDWD - Get Free Report)'s stock had its "buy" rating reiterated by HC Wainwright in a research note issued on Friday,Benzinga reports. They currently have a $25.00 target price on the biopharmaceutical company's stock. HC Wainwright's price target suggests a potential upside of 49.52% from the company's current price.

MediWound Stock Performance

NASDAQ:MDWD traded up $0.71 during midday trading on Friday, reaching $16.72. 115,420 shares of the stock traded hands, compared to its average volume of 67,020. The company has a fifty day moving average of $17.24 and a 200 day moving average of $17.62. MediWound has a 12 month low of $11.04 and a 12 month high of $24.00. The stock has a market capitalization of $180.34 million, a P/E ratio of -5.77 and a beta of 0.80.

MediWound (NASDAQ:MDWD - Get Free Report) last posted its quarterly earnings results on Tuesday, November 26th. The biopharmaceutical company reported ($0.98) EPS for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.50). MediWound had a negative net margin of 142.29% and a negative return on equity of 82.17%. During the same quarter in the prior year, the business earned ($0.24) EPS. On average, analysts predict that MediWound will post -2.6 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. MetLife Investment Management LLC bought a new position in MediWound in the 3rd quarter worth $89,000. Rhumbline Advisers bought a new position in MediWound in the 2nd quarter worth $131,000. Barclays PLC raised its holdings in MediWound by 311.3% in the 3rd quarter. Barclays PLC now owns 11,163 shares of the biopharmaceutical company's stock worth $202,000 after purchasing an additional 8,449 shares in the last quarter. Point72 Asset Management L.P. bought a new position in MediWound in the 3rd quarter worth $212,000. Finally, Bank of New York Mellon Corp bought a new position in MediWound in the 2nd quarter worth $342,000. 46.83% of the stock is currently owned by institutional investors.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.